The complete cell biological analysis of human guanylin, a recently discovered regulatory peptide, is offered in this investigation: (i) the nucleotide sequence of the gene, (ii) the isolation and characterization of its circulating molecular form, and (iii) its localization in enterochromaffin cells of the gut. As determined by molecular cloning, DNA sequencing, and comparison with the known cDNA sequence, the approximately 2.6-kbp large gene consists of three exons interrupted by two introns. The putative promoter region contains a TTTAAAA sequence motif and several potential binding sites for transcription factors such as AP-1, AP-2, Sp 1, and glucocorticoid receptors. The isolated hormonal form of guanylin is a 94-amino acid peptide with a molecular mass of 10.3 kDa. Western blot analysis of RP-HPLC fractions from blood plasma confirms this molecular form. Thus, guanylin is synthesized by gut enterochromaffin cells as a prohormone of 115 amino acids and is processed to the molecular form of 94 amino acids circulating in the blood.
Guanylin is the first known endogenous peptide activating guanylyl cyclase C (GC-C), a receptor type earlier shown to be present in the apical epithelium of the small intestine (1) . The original isolation of guanylin from rat jejunum resulted in the discovery of a small peptide containing 15 amino acids and two disulfide bonds (2) . Previously known ligands of GC-C are several heat-stable enterotoxins of enterobacteriaceae causing diarrhea in humans and animals (1) . The nucleotide sequences of the corresponding rat, mouse, and human guanylin cDNAs have been published (3) (4) (5) (6) , and translation of the cDNA sequences into amino acid sequences showed that the guanylin precursor of 115 amino acids contains the bioactive peptide isolated from rat intestine at its C terminus. However, it is not clear whether the isolated peptide is the product of a natural processing of the prohormone or of an artificial cleavage. Northern analysis confirms that guanylin is synthesized in the gut, especially in its distal segments (5) . Guanylin is thought to modulate intestinal water/electrolyte transport in a paracrine mode (3, 4, 7, 8) . This investigation reports data on the structure of the human genesl and the circulating form of its product as well as the identification of the guanylin-containing cells in the human intestine.
MATERIALS AND METHODS Molecular Biological Methods. PCRs. PCRs (9) were carried out in a thermocycler 9600 (Perkin-Elmer), using Thermus aquaticus (Taq) DNA polymerase (Biomol, Hamburg, Germany) at 2.5 units/100,l. Total RNA from human duodenum was isolated by means of an automatic nucleic acid extractor 340 (Applied Biosystems). The cDNA first strand was synthesized by using 5 ,ug of total RNA, Moloney murine leukemia virus reverse transcriptase (GIBCO/BRL), and a synthetic oligo(dT) primer [UNIP-2, CCTGAATTCTAGAGCT-CA(T)17]. Aliquots (1/30) of the synthesis reaction mixtures were subjected to reverse transcription (RT)-PCR amplifications. For verification of the human guanylin gene promoter region by PCR, three sense primers located downstream (HGU-18, CACCCCTCTCTCGGGCACTG) and upstream (HGU-19, TTTAAAAGTCCCGCCGCTTC; HGU-20, CTC-GAGCCTTATCTGATAAGG) from the region surrounding the putative transcription initiation site were constructed and used together with the antisense primer HGU-2 (CTAG-CATCCGGTACAGGCAGCGTAGG; see Fig. 1 ) and human duodenum first-strand cDNA. Genomic library screening. A human genomic library in Lambda Fix II (Stratagene, catalog no. 9462039) was screened as described (10) . The hybridization probe used was a partial rat guanylin cDNA PCR fragment (GenBank accession no. X67669) that had been [a-32P]dCTPlabeled by using a random primed labeling kit (Boehringer Mannheim). DNA sequencing. The nucleotide sequence of the guanylin gene was determined on both strands according to the method of Sanger et al. (11) , using a fluorescence sequencer 373 A (Applied Biosystems) (12) and a radioactive sequencing system (Macrophor, Pharmacia). Southern blotting. Restriction fragments of recombinant phage DNA and PCR products were checked for guanylin gene specificity by Southern hybridization (13), using the partial guanylin cDNA fragment mentioned or the oligonucleotide HGU-17 (CCAGGCCCCAAG-GAGGCACAGTGC; see Fig. 1 ) as a probe.
Peptide Synthesis and Antisera. According to the published human proguanylin sequence (5, 6, 14) the peptides guanylin-(25-37), guanylin-(34-46), and [Lys'00]guanylin-(101-115) were synthesized as described previously (7) . Polyclonal rabbit antisera K39 [recognizing guanylin-(25-37)], K42 [recognizing guanylin-(34-46)], and K605 [recognizing guanylin-(101-115)] were raised (for details, see refs. 7 and 15). In addition, antisera against serotonin and chromogranin A (7, 16, 17) were used for the identification of endocrine cells.
Characterization of the Circulating Form of Human Guanylin. Purification. Circulating human guanylin was purified from human hemofiltrate by using a method described in detail (14, 18) . Crude polypeptide extracts were obtained from 10 liters of hemofiltrate and purified by two reverse phase (RP)-HPLC steps (15) . In each HPLC step, the guanylincontaining fractions were identified by the T84-cell bioassay and by RIA. Aliquots from the fractions of the second HPLC Abbreviations: GC-C, guanylyl cyclase C; RT, reverse transcription; Is, short-circuit current. §To whom reprint requests should be addressed. IThe sequence reported in this paper has been deposited in the GenBank data base (accession no. X74322).
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step were used for Western blot analysis and for Ussing chamber studies. T84-cell bioassay. The cGMP generation by GC-C of human colon carcinoma cells (T84, passages 20-26, American Type Culture Collection) was used as a bioassay (14) . Guanylin RIA. The guanylin concentration in HPLC fractions was determined by RIA (15) . Western blot analysis. Samples of the HPLC fractions from the second purification step were analyzed by Tricine/SDS/PAGE (19) in 17.5% polyacrylamide gels and electroblotted onto hydrophobic polyvinylidene difluoride (PVDF)-based membranes (Pall) as described (7, 15) . The membranes were incubated overnight at 4°C with the guanylin antisera K39, K42, or K605, each in a 1:1000 dilution. Immunoreactive polypeptides were visualized after incubation with alkaline phosphatase-conjugated goat antibody to rabbit IgG (1:8000; Sigma), using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as chromogens (Sigma). Ussing chamber studies. Mucosal sheets from rat proximal colon were dissected, mounted in Ussing chambers, and automatically voltage clamped (20 Immunohistochemistry. Specimens of human small intestine obtained from patients undergoing major gut surgery were fixed in Bouin fluid (without acetic acid) for 20 h. They were dehydrated with ethanol, cleared in xylene, and embedded in paraffin. Consecutive sections were cut at 4 ,um and mounted on glass slides. After removal of paraffin by xylene and subsequent descending ethanol series, the sections were alternatively immunostained for guanylin (antiserum K42, diluted 1:1000; antiserum K605, diluted 1:1000), serotonin (diluted 1:20,000), and chromogranin A (diluted 1:8000) by the avidinbiotin-peroxidase complex (ABC) technique with incubation sequences as described (7) . Specificity of immunostaining was verified by appropriate controls (7, 16, 17) .
RESULTS
Characterization of the Guanylin Gene. We screened 400,000 clones of a human genomic library in A under substringent conditions with the above-mentioned partial rat guanylin cDNA fragment as a probe [hybridization: 50°C, 12 h in 1 M NaCl/50 mM Tris-HCl, pH 7.5/0.1% SDS/10% (wt/vol) dextransulfate; final washing: 20 min in 2x SSC/0.1% SDS at hybridization temperature]. One clone (phHGU 35) was finally verified as true positive. Sst I restriction fragments of the insert were then subcloned in pBSK+, and two clones (pHGU 35-4, 4.0-kbp insert; pHGU 35-9, 0.5-kbp insert), which together contained the whole gene, were sequenced. An overlapping fragment was generated by PCR amplification of recombinant phage DNA and sequenced directly.
The gene spans -2.6 kbp and consists of three exons which are split by two introns (Fig. 1 Characterization of the Circulating Guanylin. Circulating guanylin was purified from human hemofiltrate. Guanylin bioactivity (assayed by the T84-cell test) and immunoreactivity co-eluted in the identical HPLC fractions (fractions [29] [30] [31] contained higher concentrations, and fractions 28 and 32 contained low amounts of guanylin) (Fig. 3) . The RIA recognizes the circulating 10.3-kDa form of human guanylin (15) .
Western blot analysis was performed with aliquots of the HPLC fractions from the second purification step. The three antisera K39, K42, and K605 identified the major content of guanylin in the HPLC fractions [29] [30] [31] (Fig. 3) , whereas lesser amounts were detected in fractions 28 and 32. In fractions 29-31 a strongly stained peptide band in the range of 10-11 kDa was identified. Further immunoreactive bands were observed above 20 kDa, appearing in a wide range of the HPLC fractions. The fractions showing'only the high molecular mass substance contained no measurable bioactive guanylin, suggesting a nonspecific crossreaction.
In Ussing chamber experiments with rat intestinal mucosa, fractions [29] [30] [31] added to the bathing solution of the mucosal compartment evoked distinct successive increments in ISc without changes in transepithelial conductance (Fig. 4) . This effect occurred within minutes and was long lasting. As an example, the aliquot of fraction 30 added to the Ussing chamber could be calculated from the results of the RIA to correspond to a concentration of 45 nM guanylin. When this amount of fraction 30 was administered, IC was increased by 33 ± 5 gA/cm2 (n = 3) (Fig. 4) . In comparison, in the same experiments 10 nM synthetic rat guanylin-(101-115) increased ISC by 35 ± 7 ,uA/cm2. The effect of HPLC fractions 29-31 on ISC was inhibited when 0.1 mM bumetanide (Na+/K+/2Cl-cotransport inhibitor) was added to the serosal compartment. This indicates that the increase in IC is due to stimulation of electrogenic chloride secretion (Fig. 4) . Thus, the results obtained by the three methods generally concur.
Immunohistochemistry. When guanylin antisera K42 and K605 were used an intense immunostaining was detected in cells located in the epithelium of the small intestine (Fig. 5) . Guanylin immunoreactivity was distributed in a population of cells that also react with chromogranin A antibodies. These cells constitute a subpopulation of the serotonin-containing enterochromaffin cells which are found in the mucosal epithelium of the crypt region and to a lesser extent in the villi. Strong guanylin immunoreactivity was present in the basal cytoplasmic region of these cells, where the secretory granules are predominantly clustered (Fig. 5) (22, 23) , Sp 1 (24) , GRE (25) , GRE/2 (26), and GCF (27) for the corresponding transcription factors and elements; IR, inverted repeat; C/EBP, enhancer core sequence (28) ; ARES, putative acute response element (29) ; and SCM, SCM-inducible factor site (30 assays with human duodenum and jejunum mRNA and two different primers showed a high background of nonspecific signals (data not shown) which did not allow an unambiguous interpretation. However, our RT-PCR results indicate a location of this site between positions 346 and 385 of the gene. As mentioned above, these data are based on the assumption that for a successful amplification at least the 3'-terminal halves of the primers have to hybridize with the cDNA. Related to the identified weak TATA-box motif (TTTAAAA), the adenosine in position 367 is the most probable cap site (Fig. 1) .
In contrast to Wiegand and coworkers (5), we found that two nucleotides of the gene which correspond to the first two nucleotides (TC) of the cDNA sequence are arranged in reverse order (CT). This could be due to an error in the published cDNA sequence, which is supported by the fact that the CT order is also present in mouse and rat cDNA (3, 4, 6) .
The presumed promoter region exhibits sequence motifs which could be assigned to well- transcription factors such as AP-1 and Sp 1 (Fig. 1) . Furthermore, we could identify a potential glucocorticoid response element in intron I (GRE, position 718) and an equivalent half-site (position 367). Similar sequences that mediate transcription control by steroids have been detected in the promoter of the human metallothionein IIA gene (33) and the human growth hormone gene (34) . In this context it is interesting to correlate blood guanylin levels to steroiddependent diseases or to study cell lines producing guanylin. At position 582 we found the motif TCCCAG, which is homologous to the consensus sequence of elements located in hepatic genes responsible for interleukin-6-driven acute-phase reactions (29) . Furthermore, a fos-gene-homologous motif is present in intron I, showing a postulated sis-conditioned medium-inducible element (30) .
Besides the regions homologous with already-characterized regulatory elements, we identified several inverted repeats (Fig. 1) . These sequence motifs could serve as potential target sites for transcription factors or exhibit prominent secondary structures. For example, the potential binding sites for Sp 1 and AP-1 are located within inverted repeat structures. Other striking sequences are some remarkable G+C-rich stretches (positions 106 and 210), and the importance of these motifs as regulatory elements has to be verified experimentally. 
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Considering the present study with respect to functional and biochemical data, several intriguing questions must be raised. Here it is shown unambiguously that the guanylin system, in addition to its paracrine intestinal function, may constitute an endocrine system. This is supported by the fact that several organs are known to express GC-C (3, 35, 36) , and the significance of this widespread distribution is not yet understood. Furthermore, there is still discrepancy about the existence of certain molecular forms of guanylin and their bioactivity. Expression of the human full-length guanylin cDNA in human embryonic kidney 293 cells resulted in a secreted polypeptide of 10,337 Da (6), the molecular form which corresponds to the naturally processed circulating guanylin (14) . According to the results of our study, the 94-amino acid circulating guanylin is strongly bioactive. Some reported findings are in contrast because the recombinant large molecular form of 94 amino acids was found to be biologically inactive (6) or to exhibit low receptor affinity (37) . The polypeptide may be activated by protease treatment, resulting in smaller Cterminal fragments-e.g., of 22 and 32 amino acids (6, 37), or by acid treatment (3) , which activates the precursor-like polypeptide by an unknown mechanism. Further investigations are necessary to clarify the natural path of guanylin metabolism in both its paracrine and endocrine systems and to understand the precise mode of interaction with its receptor(s). The counterpart of the originally isolated rat guanylin of 15 amino acids (2), however, was not detected in our experiments with human hemofiltrate. This fragment may be artificial, but there is no doubt that the prerequisite structure of guanylin for bioactivity must include this C terminus exhibiting the two cysteine bridges.
Concerning the cellular source of intestinal guanylin, contradictory results have been published. By using in situ hybridization, guanylin expression was localized in Paneth cells of the crypts of Lieberkuhn (6) and, contrariwise, in the enterocytes of the intestinal mucosa (38) . Our previous findings showed that, in the guinea pig, guanylin immunoreactivity is localized in enterochromaffin cells (7), which is confirmed for humans in this work. The localization in Paneth cells by in situ hybridization as depicted by DeSauvage and coworkers (6) is, in our opinion, not conclusive: it may well be that the labeling shown in their paper stems from enterochromaffin cells adjacent to Paneth cells, not discriminated by the method applied in this investigation. The localization of guanylin in enterocytes (38) is barely understandable according to our results. Further studies using in situ hybridization are needed to clarify this point. In any case, the presence of guanylin in enterochromaffin cells of the gut is certainly in line with the high amounts of this peptide released into the bloodstream (15 (38) (39) (40) and (ii) into the blood stream. The luminocrine role of guanylin in the regulation of intestinal fluid secretion represents a paracrine secretion. On the other hand, the role of the hormonal form of guanylin, released at the basal side of enterochromaffin cells, requires further investigation.
